Application of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node Dissection

Phase 4CompletedNCT01914692

First Affiliated Hospital, Sun Yat-Sen University2 enrolled

Overview

Gastric cancer radical surgery related complications are common.Somatostatin is a conventional medical therapy for bleeding.This study explore the effect of Somatostatin for Advanced Gastric Cancer After D2 Lymph Node dissection.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Gastric Cancer After D2 Lymph Node Dissection

Interventions

SomatostatinDRUG

Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: 1. More than eighteen years old 2. Gastric cancer diagnosed by pathological examination 3. Be given informed consent 4. Without diabetes/hyperthyroidism/Damages of functions of heart, liver and kidney/Systemic Infection/immunodeficiency Exclusion Criteria: 1. Contraindication of vascular puncture operation 2. Patients who refused to take part in the programe 3. Poor compliance of treatment 4. Malnutrition,BMI\<18 5. with pancreatectomy

Outcomes

Primary Outcomes

fistula of pancreas

number of patients

Time frame: one year

Secondary Outcomes

amount of bleeding

amount of bleeding after the operation

Time frame: six months

seroperitoneum

seroperitoneum volum of patients

Time frame: six months

infection of incisional wound

number of patients

Time frame: one year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.